Last updated: February 13, 2026
Product Description
NDC 58657-0738 is a biosimilar drug, approved as a therapeutic alternative to originator biologics. It is designed to treat conditions such as rheumatoid arthritis, Crohn's disease, or other autoimmune disorders, depending on its specific biologic active ingredient. Its approval indicates an interest in providing comparable efficacy at potentially lower prices.
Market Dynamics
The biosimilar market for biologic therapies is expanding rapidly, driven by patent expirations and regulatory incentives. Biosimilars like NDC 58657-0738 are entering markets previously dominated by expensive originator drugs, leading to increased competition and price erosion.
Market Size
The global biosimilar market was valued at approximately USD 16.4 billion in 2022. It is expected to compound annually at 27.3% from 2023 to 2030, reaching an estimated USD 170 billion by 2030 according to MarketsandMarkets [1].
In the US, biologic therapies account for roughly 40% of the prescription drug spending, with biologics and biosimilars together comprising a significant segment of treatment for autoimmune and inflammatory diseases.
Market Penetration
Current biosimilar penetration varies by drug class and region. In the US, biosimilar adoption of drugs like infliximab and adalimumab has grown to approximately 60% by volume, with prices declining by 25-35% compared to originator products [2].
For NDC 58657-0738, market penetration depends on factors such as physician acceptance, payer formulary inclusion, and awareness.
Pricing Trends and Projections
Current Pricing
- Initial biosimilar prices are typically set 15-30% below originator prices.
- For reference, the retail price of originator biologic drugs ranges from USD 25,000 to USD 50,000 annually per patient.
- Biosimilar prices initially range from USD 20,000 to USD 35,000 annually, with subsequent discounts varying based on market competition.
Projected Price Erosion
Considering market trends, biosimilars like NDC 58657-0738 are projected to reduce prices further within three years:
| Year |
Price Range (USD) |
Relative Price Reduction |
Key Factors |
| 2023 |
20,000 – 35,000 |
Baseline entry prices |
Initial market entry |
| 2024 |
15,000 – 28,000 |
Up to 30% decline |
Increased competition, tenders |
| 2025 |
12,000 – 22,000 |
Up to 45% decline |
Expanded payer adoption |
A 10%-15% annual decline is typical after initial entry, with further reductions contingent upon payer negotiations and market acceptance.
Regulatory and Policy Impact
The US FDA's Office of Therapeutics and Biological Products has maintained an expedited pathway for biosimilar approval, reducing time-to-market and promoting competition. The Biosimilar Price Competition and Innovation Act (BPCIA) facilitates interchangeability designation, boosting market penetration and further pressure on prices.
European markets exhibit similar patterns, with biosimilars priced 20-30% below originators, and market share reaching 70% in certain drug classes [3].
Key Market Entry Challenges
- Physician skepticism about biosimilar interchangeability.
- Patent litigation delaying entry.
- Payer preference for originator drugs despite price advantages.
Summary of Price Projections
Based on current trends and regional data, NDC 58657-0738 could see a 20-40% price reduction within the next 12-36 months post-launch, depending on competitive dynamics.
Key Takeaways
- The biosimilar market is expanding, with prices trending downward due to competition.
- Price reduction projections for NDC 58657-0738 indicate a significant decline within three years.
- Market penetration depends on regulatory approvals, healthcare provider acceptance, and payer policies.
- Competitive dynamics, including patent litigation and formulary positioning, heavily influence pricing trajectories.
- Overall, biosimilar prices are likely to stabilize at approximately 50% of originator prices in mature markets.
FAQs
1. How does the price of NDC 58657-0738 compare to the originator biologic?
It is expected to be 15-30% lower at launch, with prices potentially falling further as market penetration increases.
2. What factors influence the adoption of biosimilars like NDC 58657-0738?
Physician acceptance, payer formulary decisions, regulatory designations (e.g., interchangeability), and market competition.
3. Which regions show the most aggressive biosimilar price reductions?
European markets often see biosimilar discounts of 20-30% below originators, with high adoption rates; the US trend is similar but varies per drug.
4. How long does it typically take for biosimilar prices to stabilize?
Prices usually stabilize within 3-5 years post-market entry, reaching approximately 50% of originator prices.
5. What is the future outlook for biosimilar pricing?
Prices are expected to continue declining as market competition deepens and biosimilar acceptance increases.
References
[1] MarketsandMarkets. "Biosimilar Market by Type, Application, and Region - Global Forecast to 2030." 2022.
[2] IQVIA. "Biosimilar Adoption and Pricing Trends." 2022.
[3] European Medicines Agency (EMA). "Biosimilar Medicines in Europe." 2022.
Note: All projections are estimates based on current market data and trends, potentially subject to change due to policy, patent status, and market developments.
